IGF1R and breast carcinoma: In addition, miR-7-5p can increase thesensitivity of breast carcinoma cells to adriamycin after inhibiting the epidermalgrowth factor (EGF) receptor/PI3K signaling pathway [43], and can inhibit the proliferation and metastasis of osteosarcomacells by targeting insulin-like growth factor 1 receptor [44].